PO.TB10.04 · 肿瘤生物学

效应性调节性T细胞浸润、ARID1A状态与卵巢透明细胞癌的离体抗PD-1应答:来自高级别浆液性卵巢癌对照队列的启示

Effector regulatory T-cell infiltration, ARID1A status, and Ex Vivo anti-PD-1 response in ovarian clear cell carcinoma: Insights from a comparative high-grade serous ovarian cancer cohort

编号 7445 展板 29 时间 4/22 09:00–12:00 区域 Section 28 主讲 Junsik Park, MD;PhD
分会场 Microenvironmental Determinants of Therapy Response and Resistance 2
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Junsik Park1, Eun Kyung Kim2, Jung Chul Kim1, Nari Kim3, JooHyang Lee3, Sunghoon Kim3, Sang Wun Kim3, Yong Jae Lee3, Jung-Yun Lee3

1Department of Obstetrics and Gynecology, Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of,2Department of Pathology, National Health Insurance Service Ilsan Hosp., Goyang, Korea, Republic of,3Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea, Republic of

摘要 Abstract

中文摘要
近期试验提示免疫检查点阻断(ICB)在卵巢透明细胞癌(OCCC)中可能有益,但调节ICB应答的免疫背景和生物标志物仍知之甚少。我们表征了OCCC中的肿瘤浸润淋巴细胞(TILs),并探讨了其与临床特征、离体基于抗PD-1的ICB反应性以及生物标志物表达的关联。从OCCC患者(n=55)中获取外周血单个核细胞(PBMCs)和TILs。通过多色流式细胞术分析免疫检查点受体和转录因子的表达。用抗CD3加抗PD-1(联合或不联合抗CTLA-4)离体刺激TILs,通过T细胞分裂评估增殖。通过肿瘤组织免疫组化评估HER2、ARID1A和L1CAM表达。55例患者中有20例为III/IV期或复发疾病,且大多数肿瘤为3级。在可评估的肿瘤中,9/38表现出HER2 2+/3+,24/41显示ARID1A缺失,29/41显示L1CAM高表达。在流式细胞分析中,与外周血相比,CD8 T细胞和调节性T细胞(Tregs)在肿瘤中富集。CD8+ TILs表现出深度耗竭表型,与血液中CD8+ T细胞相比,PD-1、CTLA-4和TOX更高,TCF-1表达更低,而肿瘤反应性CD39+CD103+ CD8 TILs也更富集。Tregs表现出高度抑制性特征,免疫检查点受体、CD39和CCR8增加,且效应性Tregs(CD45RA−FoxP3high)在III/IV期或复发肿瘤中比I/II期疾病更丰富。在离体试验中,一部分患者的CD8 TILs显示出强烈的抗PD-1诱导增殖,且效应性Treg频率与抗PD-1诱导的CD8 T细胞再激活呈负相关。ARID1A缺陷型肿瘤表现出显著更低的效应性Treg浸润,而HER2和L1CAM表达与T细胞表型或抗PD-1应答无明确关联。与我们此前报道的晚期高级别浆液性卵巢癌(HGSOC)队列相比,肿瘤浸润性Tregs的百分比,特别是4-1BB+ Tregs,在晚期/复发OCCC中低于HGSOC。总之,OCCC表现出CD8 TILs的深度耗竭,同时伴有高度抑制性Tregs的浸润。效应性Treg频率与抗PD-1诱导的CD8 T细胞再激活呈负相关,且ARID1A缺失可能与更有利于基于抗PD-1的免疫检查点阻断的肿瘤微环境相关。这一假说可能有助于解释OCCC相比HGSOC所报道的较高ICB应答率,但需要在更大的临床队列以及阐明ARID1A缺失如何重编程OCCC肿瘤免疫微环境的机制研究中加以证实。
查看英文原文 English abstract
Recent trials suggest potential benefit of immune checkpoint blockade (ICB) in ovarian clear cell carcinoma (OCCC), but the immune contexture and biomarkers that modulate ICB response remain poorly understood. We characterized tumor-infiltrating lymphocytes (TILs) in OCCC and explored associations with clinical features, ex vivo anti-PD-1-based ICB responsiveness, and biomarker expression. Peripheral blood mononuclear cells (PBMCs) and TILs were obtained from patients with OCCC (n=55). Immune checkpoint receptor and transcription factor expression were analyzed by multicolor flow cytometry. TILs were stimulated ex vivo with anti-CD3 plus anti-PD-1 with or without anti-CTLA-4, and proliferation was assessed by T-cell division. HER2, ARID1A, and L1CAM expression were evaluated by immunohistochemistry on tumor tissue. Twenty of 55 patients had stage III/IV or recurrent disease, and most tumors were grade 3. Among evaluable tumors, 9/38 exhibited HER2 2+/3+, 24/41 showed loss of ARID1A, and 29/41 showed high L1CAM expression. In flow cytometric analysis, CD8 T cells and regulatory T cells (Tregs) were enriched in tumors compared with peripheral blood. CD8⁺ TILs showed a profoundly exhausted phenotype, with higher PD-1, CTLA-4, and TOX and lower TCF-1 expression than CD8⁺ T cells in blood, while tumor-reactive CD39⁺CD103⁺ CD8 TILs were also more enriched. Tregs exhibited highly suppressive features with increased immune checkpoint receptors, CD39, and CCR8, and effector Tregs (CD45RA⁻FoxP3high) were more abundant in stage III/IV or recurrent tumors than in stage I/II disease. In ex vivo assays, CD8 TILs from a subset of patients showed robust anti-PD-1-induced proliferation, and effector Treg frequency was inversely associated with anti-PD-1-induced CD8 T-cell reinvigoration. ARID1A-deficient tumors exhibited significantly lower effector Treg infiltration, whereas HER2 and L1CAM expression were not clearly associated with T-cell phenotypes or anti-PD-1 response. When compared with our previously reported cohort of advanced-stage high-grade serous ovarian cancer (HGSOC), the percentage of tumor-infiltrating Tregs, particularly 4-1BB⁺ Tregs, was lower in advanced/recurrent OCCC than in HGSOC. In conclusion, OCCC exhibits profound exhaustion of CD8 TILs alongside infiltration of highly suppressive Tregs. Effector Treg frequency was inversely associated with anti-PD-1-induced CD8 T-cell reinvigoration, and ARID1A loss may be linked to a tumor microenvironment more permissive to anti-PD-1-based immune checkpoint blockade. This hypothesis may help explain the high ICB response rate reported in OCCC compared with HGSOC and requires confirmation in larger clinical cohorts and mechanistic studies elucidating how ARID1A loss in OCCC reprograms the tumor immune microenvironment.
利益披露 Disclosure
J. Park, None.. E. Kim, None.. J. Kim, None.. N. Kim, None.. J. Lee, None.. S. Kim, None.. S. Kim, None.. Y. Lee, None.. J. Lee, None.

← 返回 AACR 2026 检索